Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli
Inventors
Yoon, Seong Jun • Son, Jee Soo • KIM, In Hwang • Paik, Hyoung Rok • IM, Hyun Joo • YU, Hyun Jin • Kim, Beom Seok • Lee, Geun Woo • JUN, Soo Youn • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11701398-B2
Publication Date
2023-07-18
Expiration Date
Abstract
A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Podoviridae bacteriophage (Esc-COP-30) having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Podoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage.
Core Innovation
The disclosed invention relates to a Podoviridae bacteriophage Esc-COP-30, deposited in the Korean Collection for Type Cultures (KCTC) under accession number KCTC 14032BP, and a pharmaceutically acceptable carrier for use in preventing or treating infections or diseases caused by pathogenic Escherichia coli. Esc-COP-30 is characterized by a genome represented by a sequence as set forth in SEQ ID NO: 1 and an ability to lyse pathogenic Escherichia coli.
The patent describes that the disclosed composition is adapted for treating infection or disease caused by pathogenic Escherichia coli, where Esc-COP-30 is provided at a concentration of 1×10^4 to 1×10^15 pfu/ml or 1×10^4 to 1×10^15 pfu/g. The disclosure further specifies target pathogenic E. coli types including enterohemorrhagic E. coli, enterotoxigenic E. coli, enteroinvasive E. coli, enteropathogenic E. coli, enteroaggregative E. coli, and carcinogenic E. coli, together with listed disease indications such as food poisoning, gastroenteritis/diarrhea, urinary tract infection, neonatal meningitis, hemolytic-uremic syndrome, and septicemia.
The patent provides characterization and experimental support for Esc-COP-30, including major structural protein sizes (approximately 43, 48, 63, 75, 85, and 142 kDa), latent period, and burst size. The disclosure reports that in vitro inhibition/lysis and one-step growth curve results are consistent with the described latent period and burst size ranges, and that in animal model studies Esc-COP-30 administration shows preventive and therapeutic effects, including reduced diarrhea/diarrhea index in pigs and improved survival in mice after administration.
Claims Coverage
The document contains two independent claims, one for a composition and one for a method, each centered on Esc-COP-30 (Podoviridae) with a genome represented by SEQ ID NO: 1 and a defined concentration range expressed as pfu/ml or pfu/g. The main inventive features are the specific phage identity/genome, the lytic capability against pathogenic Escherichia coli, and the adaptation of treatment via the defined concentration ranges.
Esc-COP-30 composition for treating pathogenic Escherichia coli
A composition for treating an infection or disease caused by a pathogenic Escherichia coli comprising a Podoviridae bacteriophage Esc-COP-30 (KCTC 14032BP) having an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence as set forth in SEQ ID NO: 1, and a pharmaceutically acceptable carrier, wherein Esc-COP-30 has a concentration of 1×10^4 to 1×10^15 pfu/ml or 1×10^4 to 1×10^15 pfu/g and the composition is adapted for treating the infection or disease caused by the pathogenic Escherichia coli.
Esc-COP-30 method for treating pathogenic Escherichia coli by administration and lysis
A method for treating an infection or disease caused by a pathogenic Escherichia coli comprising administering to a subject a Podoviridae bacteriophage Esc-COP-30 (KCTC 14032BP) having an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence as set forth in SEQ ID NO: 1, and lysing the pathogenic Escherichia coli by the Podoviridae bacteriophage, wherein the Podoviridae bacteriophage Esc-COP-30 has a concentration of 1×10^4 to 1×10^15 pfu/ml or 1×10^4 to 1×10^15 pfu/g.
Overall, the claims cover both a treatment composition and a treatment method that rely on the Podoviridae bacteriophage Esc-COP-30 with a genome represented by SEQ ID NO: 1 and an ability to lyse pathogenic Escherichia coli, with the phage provided at a defined concentration range in pfu/ml or pfu/g.
Stated Advantages
Preventing and treating infections or diseases caused by pathogenic Escherichia coli using a pharmaceutically acceptable carrier with Esc-COP-30.
Shows experimental preventive and therapeutic effects in animal model studies, including reduced diarrhea/diarrhea index in pigs and improved survival in mice.
Documented Applications
Preventing and treating pathogenic Escherichia coli infection or disease, including food poisoning, gastroenteritis/diarrhea, urinary tract infection, neonatal meningitis, hemolytic-uremic syndrome, septicemia, pneumonia, shigellosis/dysentery, and cancer.
Animal model use in pigs to reduce diarrhea/diarrhea index and animal model use in mice to improve survival after administration of Esc-COP-30.
Interested in licensing this patent?